Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Yifan Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0283-0468; OpenAlex author ID A5100376928. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 1 paper

Papers 8

  1. Progesterone receptor potentiates macropinocytosis through CDC42 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41389-024-00512-7↗
  2. A low amino acid environment promotes cell macropinocytosis through the YY1-FGD6 axis in Ras-mutant pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-021-02159-9↗
  3. Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment. Last author DOI 10.1136/gutjnl-2020-323014↗
  4. The short isoform of PRLR suppresses the pentose phosphate pathway and nucleotide synthesis through the NEK9-Hippo axis in pancreatic cancer. Co-author DOI 10.7150/thno.51712↗
  5. LyP-1-fMWNTs enhanced targeted delivery of MBD1siRNA to pancreatic cancer cells. Co-author DOI 10.1111/jcmm.14864↗
  6. High cytoplasm HABP1 expression as a predictor of poor survival and late tumor stage in pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1016/j.ejso.2018.09.020↗
  7. LRG-1 promotes pancreatic cancer growth and metastasis via modulation of the EGFR/p38 signaling. First author DOI 10.1186/s13046-019-1088-0↗
  8. Portal vein resection and reconstruction with artificial blood vessels is safe and feasible for pancreatic ductal adenocarcinoma patients with portal vein invo… Co-author DOI 10.18632/oncotarget.20847↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhibo Xie · 5 shared papers, 2017–2022 · strength 0.59
  2. Deliang Fu · 4 shared papers, 2017–2022 · strength 0.46
  3. Hui Nie · 3 shared papers, 2021–2024 · strength 0.44
  4. Yan-Zhi Gai · 2 shared papers, 2022–2024 · strength 0.34
  5. Lie Yao · 3 shared papers, 2017–2020 · strength 0.33
  6. Chen Jin · 3 shared papers, 2017–2019 · strength 0.32
  7. Yishen Mao · 2 shared papers, 2019–2022 · strength 0.27
  8. Zhigang Zhang · 2 shared papers, 2021–2022 · strength 0.23
  9. Qing Li · 2 shared papers, 2021–2022 · strength 0.23
  10. Yongwei Sun · 2 shared papers, 2021–2022 · strength 0.23
  11. Li-Peng Hu · 2 shared papers, 2021–2022 · strength 0.23
  12. Xiaomei Yang · 2 shared papers, 2021–2022 · strength 0.23
  13. Ying-Na Liao · 1 shared paper, 2024 · strength 0.22
  14. Deliang Fu · 1 shared paper, 2020 · strength 0.13
  15. Quanjun Lin · 1 shared paper, 2020 · strength 0.13
  16. Xueli Zhang · 1 shared paper, 2022 · strength 0.12
  17. Dongxue Li · 1 shared paper, 2022 · strength 0.12
  18. Linli Yao · 1 shared paper, 2022 · strength 0.12
  19. Dejun Liu · 1 shared paper, 2022 · strength 0.12
  20. Qin Yang · 1 shared paper, 2021 · strength 0.11
  21. Gary Guishan Xiao · 1 shared paper, 2021 · strength 0.11
  22. Shu‐Heng Jiang · 1 shared paper, 2021 · strength 0.11
  23. Jichun Gu · 1 shared paper, 2017 · strength 0.07
  24. Feng Yang · 1 shared paper, 2017 · strength 0.07
  25. Yongjian Jiang · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.